Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-5 axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma
2017-001912-13Phase 2Active
- Sponsor
- Kite Pharma
- Start
- May 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in indolent lymphoma, follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and 1 more, sponsored by Kite Pharma. Primary endpoint: Overall response rate. Started May 2018; status: active.
02
Drugs
axicabtagene ciloleucel
03
Conditions
indolent lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on 2017-001912-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001912-13.